Transdermal hormone therapy causes fewer and less severe changes in breast density and less breast tenderness than oral HT, according to a study involving 202 postmenopausal women sponsored by Novartis.
Transdermal hormone therapy causes fewer and less severe changes in breast density and less breast tenderness than oral HT, according to a study involving 202 postmenopausal women sponsored by Novartis.
The two agents compared in the study were Estalis/Combipatch (Novartis, Basel, Switzerland) and Kliogest (Schering AG, Berlin, Germany).
The researchers found that mean breast density with the transdermal product was 38% versus 47% with the oral product (P<0.0001). Of the women using transdermal HT, 39% experienced no change in breast density versus 16% of the women using oral HT. Only 4% using the transdermal form had more than a 25% increase in density versus 16% of the women using the oral form. And 36% of the women in the transdermal group reported breast tenderness during the 1-year study versus 58% of the oral group (P=0.0002).
Socioeconomic disadvantage in pregnancy linked to postpartum CVD risk
February 19th 2025A new study highlights how neighborhood-level socioeconomic deprivation in early pregnancy significantly raises the long-term risk of cardiovascular disease in postpartum women, emphasizing the role of social determinants in maternal health.
Read More
Maternal hypertension and diabetes linked to worse offspring cardiovascular health
February 17th 2025A new study finds that children born to mothers with hypertensive disorders of pregnancy or gestational diabetes are at a higher risk of developing cardiovascular health issues by ages 10 to 14 years.
Read More